Tomorrow limit down

Tomorrow will gap down to 0.50

Q report not bad

Good time to collect.

Very poor management. Still sleep

This counter under ICU

California nurse tests positive over a week after receiving Pfizer COVID-19 vaccine- ABC https://www.thestar.com.my/news/world/2020/12/30/california-nurse-tests-positive-over-a-week-after-receiving-pfizer-covid-19-vaccine--abc#.X-xQqyt5NlA.whatsapp

California nurse tests positive over a week after receiving Pfizer COVID-19 vaccine- ABC https://www.thestar.com.my/news/world/2020/12/30/california-nurse-tests-positive-over-a-week-after-receiving-pfizer-covid-19-vaccine--abc#.X-xQqyt5NlA.whatsapp

Really lousy counter. Everyday drop and like dead counter. Like PN17 counter

Already bottom, time to rebound. Normally this type of stock will rebound in new year opening. A few days only you got chance grab

1 cent won’t affect lot on share price lar

1 cent dividend coming soon. Lousy stock

Yes started only

Tomorrow rebound

Good for pr tomorrow

https://www.sciencemag.org/news/2020/12/mutant-coronavirus-united-kingdom-sets-alarms-its-importance-remains-unclear

https://www.biopharma-reporter.com/Article/2020/12/21/Investigations-underway-to-see-if-new-COVID-19-variant-in-UK-has-impact-on-vaccine-effectiveness

Still can buy and keep for long term

Good for glove counter tomorrow

This MD teruk

How about company share buyback? No support also. Lousy management.

https://www.chinapress.com.my/?p=2329567

This is no new news and also no surprise news anymore, why you so worry?

Why next week fly? Any good news from AGM report?

Any news on getting new project?

Nicolas, only small kids can believe you.

Based on eps, the share should worth more than 2

Result good or no good?

Result will very good

You will see very outstanding report on this Wednesday. Buy before too late.

Vaccine approved only for emergency use, not all the country will follow United States. It still got some risk. Health care product like glove and face mask still can survive.

Vaccine approved only for emergency use, not all the country will follow United States. It still got some risk. Health care product like glove and face mask still can survive.

Vaccine approved only for emergency use, not all the country will follow United States. It still got some risk. Health care product like glove and face mask still can survive.

Vaccine approved only for emergency use, not all the country will follow United States. It still got some risk. Health care product like glove and face mask still can survive.

Vaccine approved only for emergency use, not all the country will follow United States. It still got some risk. Health care product like glove and face mask still can survive.

Vaccine approved only for emergency use, not all the country will follow United States. It still got some risk. Health care product like glove and face mask still can survive.

Vaccine approved only for emergency use, not all the country will follow United States. It still got some risk. Health care product like glove and face mask still can survive.

Glove will coming back again

FDA will likely scrutinize allergic reactions to Pfizer’s Covid vaccine in UK before clearing use in U.S., Trump vaccine chief says

PUBLISHED WED, DEC 9 20205:29 PM ESTUPDATED WED, DEC 9 20206:10 PM EST
Noah Higgins-Dunn
@HIGGINSDUNN
Allergic reactions reported by U.K. health-care workers vaccinated against Covid-19 will likely be discussed before the FDA authorizes a vaccine in the U.S., medical experts said on Wednesday.
However, the allergic reactions shouldn’t be a surprise, and people with underlying health conditions aren’t commonly included in clinical trials, they said.
The FDA is set to convene a meeting of its Vaccines and Related Biological Products Advisory Committee, or VRBPAC, on Thursday to review Pfizer’s Covid-19 vaccine.

Report out today?

The next few months of the Covid-19 pandemic will be among “the most difficult in the public health history of this nation,” Dr. Robert Redfield, the director of the Centers for Disease Control and Prevention, said Wednesday.

Redfield, speaking at an event hosted by the U.S. Chamber of Commerce, said that about 90% of hospitals in the country are in “hot zones and the red zones.” He added that 90% of long-term care facilities are in areas with high level of spread.

“So we are at a very critical time right now about being able to maintain the resilience of our health-care system,” Redfield said. “The reality is December and January and February are going to be rough times. I actually believe they’re going to be the most difficult in the public health history of this nation, largely because of the stress that’s going to be put on our health-care system.”

The next few months of the Covid-19 pandemic will be among “the most difficult in the public health history of this nation,” Dr. Robert Redfield, the director of the Centers for Disease Control and Prevention, said Wednesday.

Redfield, speaking at an event hosted by the U.S. Chamber of Commerce, said that about 90% of hospitals in the country are in “hot zones and the red zones.” He added that 90% of long-term care facilities are in areas with high level of spread.

“So we are at a very critical time right now about being able to maintain the resilience of our health-care system,” Redfield said. “The reality is December and January and February are going to be rough times. I actually believe they’re going to be the most difficult in the public health history of this nation, largely because of the stress that’s going to be put on our health-care system.”

The next few months of the Covid-19 pandemic will be among “the most difficult in the public health history of this nation,” Dr. Robert Redfield, the director of the Centers for Disease Control and Prevention, said Wednesday.

Redfield, speaking at an event hosted by the U.S. Chamber of Commerce, said that about 90% of hospitals in the country are in “hot zones and the red zones.” He added that 90% of long-term care facilities are in areas with high level of spread.

“So we are at a very critical time right now about being able to maintain the resilience of our health-care system,” Redfield said. “The reality is December and January and February are going to be rough times. I actually believe they’re going to be the most difficult in the public health history of this nation, largely because of the stress that’s going to be put on our health-care system.”

The next few months of the Covid-19 pandemic will be among “the most difficult in the public health history of this nation,” Dr. Robert Redfield, the director of the Centers for Disease Control and Prevention, said Wednesday.

Redfield, speaking at an event hosted by the U.S. Chamber of Commerce, said that about 90% of hospitals in the country are in “hot zones and the red zones.” He added that 90% of long-term care facilities are in areas with high level of spread.

“So we are at a very critical time right now about being able to maintain the resilience of our health-care system,” Redfield said. “The reality is December and January and February are going to be rough times. I actually believe they’re going to be the most difficult in the public health history of this nation, largely because of the stress that’s going to be put on our health-care system.”

Will up very soon. Report very near already. Still 2 weeks to go.

The report show a lot of improvement in revenue, I think this Monday still can up.

Report out. Good profit

Result out. Good profit

Covid testing faces delays — again — as demand spikes ahead of the holidays

PUBLISHED THU, NOV 19 202010:29 AM ESTUPDATED 6 MIN AGO
Will Feuer
@WILLFOIA
With the holidays approaching, some companies calling workers back to the office and anxiety over the virus rising with the daily case count, demand for accurate Covid-19 testing is spiking.
An average of 1.6 million Covid-19 tests were run every day over the last week, compared with a seven-day average of less than 900,000 in July.
The surge in demand is leading to long lines for testing, shortages in testing kits and other supplies and processing delays across the country.

Stocks fall as coronavirus cases rise, jobless claims data disappoint